Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A

Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A

KNSA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$7.25B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class AKiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A64.5-17%7.6-
$89.50

Target Price by Analysts

1.4% downsideKiniksa Pharmaceuticals International Plc. Target Price DetailsTarget Price
$-4.53

Current Fair Value

105% downside

Overvalued by 105% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$7.25 Billion
Enterprise Value$7.10 Billion
Earnings per Share$0.8
Beta0.09
Outstanding Shares78,192,603

Return

Return on Equity16.75%ROE
Return on Assets12.23%
Return on Invested Capital19.15%

Valuation & Multiples

P/E Ratio64.5P/E Ratio
PEG41.13PEG
Price to Sales7.57Price to Sales
Price to Book Ratio11.35Price to Book Ratio
Enterprise Value to Revenue7.51
Enterprise Value to EBIT51.16
Enterprise Value to Net Income64
Total Debt to Enterprise0
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 27, 2026
EPS Estimate
$0.37
Consensus analyst estimate
Revenue Estimate
$260.66 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 23, 2027
EPS Estimate
$0.25
Consensus analyst estimate
Revenue Estimate
$302.53 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 357.33%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.95%▼ 60.56%
Total Invested$55.16M▼ 98.16%
Investors Holding66▼ 210.00%

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals International Plc. Insider Information FAQ

In the latest 13F quarter on Stockcircle, 2 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 2 open-market insider sales for Kiniksa Pharmaceuticals International Plc. in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.